Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesNovel therapeutic approaches to the treatment of metastatic breast cancer
Cancer Treatment Reviews, 11/05/09
Fernandez Y et al. – Given the enormous amount of information about drug discovery in cancer, it is important to be familiar with the present state of the treatment of metastatic breast cancer. The purpose of this review is to provide an update on the development of some of the most promising novel agents and treatment strategies in metastatic breast cancer.
Related Articles
Pathological and molecular characteristics distinguishing contralateral metastatic from new primary breast cancer
Annals of Oncology, 11/04/09
Relevance Score: 83%
The GAB2 signaling scaffold promotes anchorage independence and drives a transcriptional response associated with metastatic progression of breast cancer
Oncogene, 10/26/09
Relevance Score: 83%
Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status
Bulletin du Cancer, 10/19/09
Relevance Score: 83%
Hormone receptor expression is associated with a unique pattern of metastatic spread and increased survival among HER2-overexpressing breast cancer patients
American Journal of Clinical Oncology, 10/06/09
Relevance Score: 83%
Quality of life and depression among metastatic breast cancer patients
Medical Oncology, 10/05/09
Relevance Score: 83%
Today in Breast...keeping you current
Receive free subspecialty "5-minute updates" via email
c-Jun activation is required for 4-hydroxytamoxifen-induced cell death in breast cancer cells
Oncogene, 11/25/09
Adenosine A1 receptor, a target and regulator of estrogen receptor action, mediates the proliferative effects of estradiol in breast cancer
Oncogene, 11/25/09
Extrapulmonary small cell carcinoma in breast and prostate
Clinical and Translational Oncology, 11/25/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
Oncogene, 11/25/09
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
Investigational New Drugs, 11/25/09
Adding more content to screening: reactivation of FOXO as a therapeutic strategy
Clinical and Translational Oncology, 11/25/09
Sponsor
Article Search
Sponsor
Sponsor